Disease relevance of 2-[(R)-[(5S)-5-carboxy-5-formamido-pentyl]carbamoyl-(2-phenylethanoylamino)methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid

• A second clinical trial of the compound Ro 6-0787, which is a specific monovalent penicilloyl hapten inhibitor of allergic reactions to penicillin has been conducted by investigators from 9 different European groups in 90 patients allergic to penicillin [1].
• It is not yet ascertained whether the occasional positive skin reactions and urticaria to Ro 6-0787 may have been due to aggregation, or incomplete dissolution of the compound or whether it reflects hypersensitivity to another antigenic determinant [1].

High impact information on 2-[(R)-[(5S)-5-carboxy-5-formamido-pentyl]carbamoyl-(2-phenylethanoylamino)methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid

• A depression of skin hypersensitivity to PPL and/or penicillin and penicillin derivatives sometimes persisting for weeks and months was obvious in numerous allergic patients submitted to combined Ro 6-0787-penicillin treatment [1].

Analytical, diagnostic and therapeutic context of 2-[(R)-[(5S)-5-carboxy-5-formamido-pentyl]carbamoyl-(2-phenylethanoylamino)methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid

• With the reservation that patients with positive skin test to Ro 6-0787 have for the time being to be excluded from combined treatment, this monovalent hapten certainly offers a new possibility to resume and/or pursue penicillin therapy in patients demonstrably allergic to that drug [1].

References